TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

On Friday, TG Therapeutics Inc common stock (TGTX) stock saw a modest uptick, ending the day at $28.81 which represents a slight increase of $0.91 or 3.26% from the prior close of $27.9. The stock ...

CONTACT: Investor Relations Email: [email protected] Telephone: 1.877.575.TGTX (8489), Option 4 Media Relations: TG Therapeutics NewsMORE Related Stocks ...

TG Therapeutics (TGTX) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.73 per share a year ago. These ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million at the mid-point. The results were slightly underwhelming but ...

TG Therapeutics develops treatments for B-cell diseases, with a primary focus on multiple sclerosis. Its lead product, Briumvi, serves as the cornerstone of its commercial success. Briumvi ...

Analysts' ratings for TG Therapeutics (NASDAQ:TGTX) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The table below summarizes their recent ratings, showcasing the ...

Greetings and welcome to the TG Therapeutics third quarter conference call and webcast. At this time, all participants are in listen-only mode. If anyone should require operator assistance ...

TG Therapeutics (TGTX) came out with quarterly ... but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus ...